Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Pharmaceutical industry

Anything to declare?

Disclosure of drug company payments to healthcare professionals is on its way in the UK — a big step towards transparency.

Database made up of rows of servers with light at the end


Around £40m is paid to healthcare professionals in the UK each year by pharmaceutical companies. These payments are unidentifiable, made available on an aggregate basis.

However, from 30 June 2016, for the first time patients will be able find out if their doctor, pharmacist or other healthcare professional has received any payments from a pharmaceutical company. The payments, which could include being paid to attend a medical event or acting as an adviser to a pharmaceutical or medical device company, will be listed on a publicly searchable database called Disclosure UK. This will be hosted by the Association of British Pharmaceutical Industry (ABPI), the trade association of companies in the UK that produce prescription medicines.

This move towards transparency has been in the making since 2013, led by the European Federation of Pharmaceutical Industries and Associations, and will be applied to 33 countries in Europe in different ways. Some will have a central platform database like the UK, others will see disclosures of payments made on company’s own websites.

Some European countries, including France, Slovakia, Greece, Romania and Denmark, have gone one step further and have passed legislation to make disclosures of payments to healthcare professionals mandatory.

In the UK, disclosures will be made by the companies who pay the healthcare professionals but payments can only be included in the database if the healthcare professional gives consent because of data protection rules. As some healthcare professionals may decline to give consent, the public may never know who the biggest recipients of money are and which company paid them. Nevertheless, the ABPI database is a step in the right direction in bringing in much needed transparency on the relationship between companies and healthcare professionals.

The good news is that the road towards transparency does not end there. Health secretary Jeremy Hunt plans to go further in the UK by bringing in a ‘sunshine rule’ (so called because it mirrors the Physician Payment Sunshine Act in the United States) on dealings between NHS personnel and companies. Under the proposal, NHS staff found to be abusing their position by taking extravagant gifts or hospitality and lobbying for unneeded or overly expensive drugs could be punished with measures such as disciplinary action, dismissal or imprisonment. The sunshine rule will have teeth.

The public puts its trust in healthcare professionals and expects them to behave in an ethical way. In 2015, NHS England launched an investigation into allegations made in a Daily Telegraph report that highlights the practice of health officials being paid to advise pharmaceutical companies on the NHS use of their products (The Pharmaceutical Journal 2015;295:105) . More recently, a Telegraph investigation revealed on 18 February 2016 that more than one in three members of the government panel overseeing the NHS’s procurement of medicines across Britain (of which at least one had been identified as an NHS procurement pharmacist) had been carrying out paid work for pharmaceutical companies.

While some healthcare professionals actively avoid conflicts of interest, others see benefits of collaboration with pharmaceutical companies in areas such as research. The introduction of a database is a welcome initiative and marks a step towards making relationships between healthcare professionals and the industry more transparent, but it remains to be seen how it works in practice and whether it has any impact on patients.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200754

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Essentials of Economic Evaluation in Healthcare

    Essentials of Economic Evaluation in Healthcare

    An introduction to economic evaluation specific to healthcare, for those with little or no knowledge of economics. Covers cost effectiveness, cost utility and cost benefit analysis.

    £33.00Buy now
  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Database made up of rows of servers with light at the end

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.